Rules concerning biological products eased

The Korea Food and Drug Administration said on July 15 that some of the rules concerning the license of biological products, including biosimilars, have been eased for ameliorating unnecessary procedures in the screening process for drug approval and making the definition of biosimilars more clear.

Under the newly revised rules, drug makers are obliged to conduct the long-term stability test...